Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Royal Caribbean Cruises Ltd (RCL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Royal Caribbean Cruises Ltd — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $281.5 (market cap $39.89B), while Royal Caribbean Cruises Ltd trades at $293.99 (market cap $76.53B). The key difference: Royal Caribbean Cruises Ltd is the larger of the two by market cap, and Royal Caribbean Cruises Ltd pays a 1.75% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | RCL | |
|---|---|---|
Market Cap | $39.89B | $76.53B |
Sector | Health | Consumer Cyclical |
52-Week High | $491.22 | $365.84 |
52-Week Low | $278.09 | $246.71 |
Enterprise Value | $38.15B | $97.81B |
Dividend Yield | — | 1.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Royal Caribbean (RCL) trades at $285.37, down 0.94% on the day, with a neutral technical signal and strong fundamental performance. The stock shows robust revenue growth, with 2025 revenue reaching $17.93 billion and net income of $4.27 billion, driving a high return on equity of 50.41%. Recent news highlights cruise industry momentum, including new ship experiences and a scheduled Q2 2026 earnings call on July 28, 2026.
Outlook remains positive given strong profitability and analyst consensus, with a price target of $328.00 implying 15% upside. Key risks include Europe demand weakness and high debt levels, though improving cash flow and Caribbean strength provide support. The stock presents a growth opportunity amid favorable industry trends, but investors should monitor execution on yield growth and cost management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Royal Caribbean Cruises Ltd
Royal Caribbean is the world's second-largest cruise company, operating 64 ships across five global and partner brands in the cruise vacation industry, with 10 more ships on order. Brands the company operates include Royal Caribbean International, Celebrity Cruises, and Silversea. The company also has a 50% investment in a joint venture that operates TUI Cruises and Hapag-Lloyd Cruises, allowing it to compete on the basis of innovation, quality of ships and service, variety of itineraries, choice of destinations, and price. The company completed the divestiture of its Azamara brand in the first quarter of 2021.
Read more on RCL →
